Madrigal Pharmaceuticals (FRA:YDO1) Interest Expense : €-13.1 Mil (TTM As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Madrigal Pharmaceuticals's interest expense for the three months ended in Mar. 2025 was € -3.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was €-13.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Madrigal Pharmaceuticals's Operating Income for the three months ended in Mar. 2025 was € -73.4 Mil. Madrigal Pharmaceuticals's Interest Expense for the three months ended in Mar. 2025 was € -3.1 Mil. Madrigal Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Madrigal Pharmaceuticals Interest Expense Historical Data

The historical data trend for Madrigal Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Interest Expense Chart

Madrigal Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-3.74

-11.66

-14.01

Madrigal Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-3.53	-3.40	-3.32	-3.34	-3.05

Madrigal Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.1 Mil.

Madrigal Pharmaceuticals (FRA:YDO1) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Madrigal Pharmaceuticals's Interest Expense for the three months ended in Mar. 2025 was €-3.1 Mil. Its Operating Income for the three months ended in Mar. 2025 was €-73.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was €109.8 Mil.

Madrigal Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Madrigal Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Madrigal Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

MDGL:USA 0JXI:UK

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

https://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals Headlines

No Headlines